Expression Therapeutics (ET) is a privately-owned biotechnology company founded in 2005 and based in Atlanta, Georgia. Our product pipeline includes a comprehensive set of products designed to improve and expand global hemophilia care. ET’s patented and patent pending core technologies are ‘expression’ elements designed to produce more effective and economical hemophilia therapeutics. Our expression-engineered cell, gene and protein-based products should revolutionize the global treatment of hemophilia.
Our mission at Expression Therapeutics is to develop novel therapies that will dramatically improve the lives of persons with hemophilia around the world.